Spirulina and traumatic brain injury: microglial NOX2, secondary injury cascade, and recovery nutrition

The secondary TBI cascade

Microglial NOX2 activation: Within hours of TBI, microglia are activated by DAMPs (damage-associated molecular patterns) from damaged neurons. Activated microglia upregulate NOX2, generating superoxide. This oxidative burst is intended to clear debris but causes significant bystander neuronal damage by lipid peroxidation of neuronal membranes, oxidation of synaptic proteins, and activation of NF-κB-driven neuroinflammatory cytokines (TNF-α, IL-1β, IL-6). Phycocyanobilin inhibits microglial NOX2, reducing this bystander damage.
Excitotoxicity: Mechanical disruption releases massive glutamate from damaged neurons. NMDA receptor overactivation drives intracellular calcium influx; mitochondrial calcium overload generates ROS from Complex I/III; this amplifies NOX2 activation in a feed-forward loop. Phycocyanobilin reduces the superoxide component of this loop, reducing the oxidative amplification of excitotoxicity without directly blocking NMDA receptors.
BBB disruption: Endothelial NOX2 activation in post-traumatic inflammation disrupts tight junction proteins (claudin, occludin), increasing BBB permeability. This allows peripheral immune cells and inflammatory mediators to enter the brain parenchyma, amplifying the inflammatory cascade. Phycocyanobilin’s endothelial NOX2 inhibition supports tight junction integrity.

TBI disrupts blood vessels in the brain parenchyma. Haemoglobin from extravasated blood is broken down by microglia; the haem iron is released as free iron, which drives Fenton chemistry (•OH generation) in a brain already under oxidative stress. Haemosiderin deposits in post-traumatic brain tissue are a marker of ongoing iron-mediated oxidative injury.
Iron supplementation timing: In the acute post-TBI phase (days to 2 weeks): do not supplement iron unless confirmed systemic iron deficiency anaemia (Hb <10 g/dL) requires correction. Oral iron supplementation in the context of intracranial haemorrhage may add to the iron-mediated oxidative burden. In the subacute and rehabilitation phase (2+ weeks): assess iron status; correct genuine iron deficiency anaemia (which impairs neurological recovery by reducing O&sub2; delivery and mitochondrial function).
Spirulina iron (2–4 mg/5 g non-haem iron) is modest. In the rehabilitation phase, spirulina’s combination of iron, protein, and phycocyanobilin (antioxidant) is a nutritionally appropriate adjunct once acute haemorrhagic risk has resolved.

Tryptophan (~45–60 mg/5 g): TBI disrupts serotonin synthesis by activating the IDO (indoleamine 2,3-dioxygenase) pathway, shunting tryptophan toward kynurenine rather than serotonin. Spirulina tryptophan provides substrate for serotonin synthesis alongside neuroinflammation reduction (phycocyanobilin reduces IDO-activating cytokines).
Tyrosine (~175 mg/5 g): Post-TBI dopamine and noradrenaline deficits from catecholaminergic tract damage contribute to cognitive and attentional impairment. Tyrosine as catecholamine precursor supports synthesis when dopaminergic pathways are intact but substrate-limited.
Complete protein: TBI patients are often hypermetabolic and hypercatabolic. Protein requirements increase to 1.5–2.5 g/kg/day in the acute/subacute phase. Spirulina’s complete protein in a small-volume format is practical when appetite is impaired during early recovery.

Phenytoin: Narrow therapeutic index; metabolised by CYP2C9 and CYP2C19. No documented spirulina pharmacokinetic interaction. Monitor phenytoin levels if dose or supplement regimen changes.
Levetiracetam, lamotrigine, valproate: No documented pharmacokinetic interaction with spirulina. Levetiracetam and lamotrigine are not significantly CYP-metabolised. Valproate inhibits CYP2C9; the interaction with spirulina is not documented.

High-dose corticosteroids are no longer used in TBI (CRASH trial showed increased mortality). If steroids are being used for other indications in TBI patients: NK stimulation from spirulina is relevant; discuss with the treating neurologist.

Acute phase (0–14 days post-TBI): Focus on medical management. Spirulina is not a priority. Do not supplement iron acutely. Small amounts (1–2 g/day) of spirulina powder in food are acceptable if tolerated; no active contraindication.
Subacute and rehabilitation phase (2+ weeks): 3–5 g/day as an antioxidant, protein, and micronutrient adjunct to support neurological recovery. Assess iron status. Begin in the context of neurological rehabilitation team awareness.
No interaction with levetiracetam or lamotrigine; phenytoin levels should be monitored as standard with any supplement change
Spirulina’s activating amino acids (tyrosine, phenylalanine) support morning cognitive function in TBI recovery — take with breakfast, not in the evening